The United States market has experienced a notable upswing, with a 2.7% increase over the last week and a substantial 21% rise over the past year, while earnings are anticipated to grow by 17% annually in the coming years. In this context of robust growth, identifying high-growth tech stocks that align with these positive trends involves looking for companies with strong innovation potential and solid financial health that can capitalize on expanding market opportunities.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	21.54%	21.27%	★★★★★★
Fabrinet	20.12%	22.27%	★★★★★★
Marker Therapeutics	64.28%	69.04%	★★★★★★
Lumentum Holdings	43.99%	56.54%	★★★★★★
Praxis Precision Medicines	64.75%	71.13%	★★★★★★
Insmed	32.17%	66.59%	★★★★★★
Madrigal Pharmaceuticals	27.97%	63.67%	★★★★★★
Syndax Pharmaceuticals	30.13%	69.82%	★★★★★★
Travere Therapeutics	24.09%	52.97%	★★★★★★
Precigen	34.82%	59.32%	★★★★★★

Let's uncover some gems from our specialized screener.

Advanced Energy Industries (AEIS)

Simply Wall St Growth Rating: ★★★★★★

Overview: Advanced Energy Industries, Inc. offers precision power conversion, measurement, and control solutions globally and has a market cap of $13.02 billion.

Operations: The company generates revenue primarily from its Power Electronics Conversion Products segment, which reported $2.04 billion in sales.

Advanced Energy Industries has demonstrated robust financial performance with a significant uptick in sales, reporting $574.1 million in Q2 2026, up from $441.5 million the previous year. This growth is mirrored in their net income which more than doubled to $54.1 million from $25.2 million, reflecting an earnings surge by over 115%. The company's strategic pursuits are equally aggressive as evidenced by their active search for acquisitions that align financially and strategically, enhancing their market position within the high-tech sector. Their commitment to shareholder returns remains strong with a recent declaration of a quarterly cash dividend of $0.10 per share, underscoring confidence in ongoing financial health and operational stability.

Insmed (INSM)

Simply Wall St Growth Rating: ★★★★★★

Overview: Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases globally, with a market cap of $28.63 billion.

Operations: The company generates revenue primarily through the development and commercialization of therapies for rare diseases, amounting to $1.14 billion.

Insmed has shown resilience with a significant reduction in net loss to $13.24 million in Q2 2026 from $321.69 million the previous year, signaling potential recovery and operational improvements. The company's focus on pulmonary treatments is underscored by promising trial results for TPIP, which demonstrated sustained efficacy and safety over 12 months. Despite recent exclusions from several Russell indexes, these clinical advancements and strategic executive appointments, like Samuele Butera as Senior VP of Global Respiratory, could enhance Insmed's profile in biotech circles.

Praxis Precision Medicines (PRAX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders in the United States, with a market cap of $10.07 billion.

Operations: Praxis Precision Medicines focuses on developing treatments for central nervous system disorders linked to neuronal excitation-inhibition imbalance. As a clinical-stage company, it primarily invests in research and development without current revenue streams from product sales.

Praxis Precision Medicines, despite a challenging financial landscape with a net loss of $83.72 million in Q2 2026, is making strategic advancements in biotechnology. The company's recent collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide highlights its commitment to innovation and broadening treatment accessibility. This partnership not only strengthens Praxis's product line but also enhances its competitive position in the market, showcasing an agile approach to overcoming R&D hurdles and extending product lifecycles. With revenue expected to grow by 64.8% annually, Praxis is poised for significant transformations as it moves towards profitability within three years, supported by promising developments like the FDA's extension for reviewing relutrigine underpinning potential future successes.

Summing It All Up

• Take a closer look at our US High Growth Tech and AI Stocks list of 22 companies by clicking here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.